Lessons learned from next-generation sequencing in head and neck cancer

Head and Neck

Volumn 35, Issue 3, 2013, Pages 454-463

  Loyo, Myriam ^a   Li, Ryan J ^a   Bettegowda, Chetan ^a   Pickering, Curtis R ^b   Frederick, Mitchell J ^b   Myers, Jeffrey N ^b   Agrawal, Nishant ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

head and neck squamous cell carcinoma; mutations; next generation sequencing; oncogene; tumor suppressor gene

Indexed keywords

CETUXIMAB; CONTUSUGENE LADENOVEC; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR; FLUOROURACIL; GAMMA SECRETASE INHIBITOR; LAPATINIB; METHOTREXATE; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN HRAS; PROTEIN P16; PROTEIN P53; PROTEIN TYROSINE KINASE; RAS PROTEIN; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ALCOHOL CONSUMPTION; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; COLORECTAL CANCER; DISEASE COURSE; DNA METHYLATION; DRUG SAFETY; FEVER; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; GENE SILENCING; GENE THERAPY; GENETIC PROCEDURES; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INJECTION SITE DISCOMFORT; INVASIVE CARCINOMA; LUNG CANCER; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROCESSING; REVIEW; RISK FACTOR; SMOKING; TREATMENT RESPONSE; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION TO DISEASE; HEAD AND NECK NEOPLASMS; HUMANS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, NOTCH1; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84874115450     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23100     Document Type: Review

References (128)

1. Haddad RI, Shin DM,. Recent advances in head and neck cancer. N Engl J Med 2008; 359: 1143-1154.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
3. Leemans CR, Braakhuis BJ, Brakenhoff RH,. The molecular biology of head and neck cancer. Nat Rev Cancer 2011; 11: 9-22.
4. Agrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011; 333: 1154-1157.
5. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011; 333: 1157-1160.
6. Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007; 357: 2552-2561.
7. Skinner HD, Sandulache VC, Ow TJ, et al. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res 2012; 18: 290-300.
8. Nylander K, Dabelsteen E, Hall PA,. The TP53 molecule and its prognostic role in squamous cell carcinomas of the head and neck. J Oral Pathol Med 2000; 29: 413-425.
9. Appella E, Anderson CW,. Post-translational modifications and activation of TP53 by genotoxic stresses. Eur J Biochem 2001; 268: 2764-2772.
10. Carr AM,. Cell cycle. Piecing together the TP53 puzzle. Science 2000; 287: 1765-1766.
11. Vogelstein B, Lane D, Levine AJ,. Surfing the TP53 network. Nature 2000; 408: 307-310.
12. Buschmann T, Fuchs SY, Lee CG, Pan ZQ, Ronai Z,. SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate TP53. Cell 2000; 101: 753-762.
13. Inga A, Storici F, Darden TA, Resnick MA,. Differential transactivation by the TP53 transcription factor is highly dependent on TP53 level and promoter target sequence. Mol Cell Biol 2002; 22: 8612-8625.
14. el-Deiry WS,. Regulation of TP53 downstream genes. Semin Cancer Biol 1998; 8: 345-357.
15. Miyashita T, Reed JC,. Tumor suppressor TP53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-299.
16. Friend S,. TP53: a glimpse at the puppet behind the shadow play. Science 1994; 265: 334-335.
17. Levine AJ,. The TP53 tumor-suppressor gene. N Engl J Med 1992; 326: 1350-1352.
18. Dittmer D, Pati S, Zambetti G, et al. Gain of function mutations in TP53. Nat Genet 1993; 4: 42-46.
19. Forastiere A, Koch W, Trotti A, Sidransky D,. Head and neck cancer. N Engl J Med 2001; 345: 1890-1900.
20. Boyle JO, Hakim J, Koch W, et al. The incidence of TP53 mutations increases with progression of head and neck cancer. Cancer Res 1993; 53: 4477-4480.
21. Ebrahimi M, Boldrup L, Coates PJ, Wahlin YB, Bourdon JC, Nylander K,. Expression of novel TP53 isoforms in oral lichen planus. Oral Oncol 2008; 44: 156-161.
22. Brennan JA, Boyle JO, Koch WM, et al. Association between cigarette smoking and mutation of the TP53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 1995; 332: 712-717.
23. Soussi T, Kato S, Levy PP, Ishioka C,. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat 2005; 25: 6-17.
24. Taylor D, Koch WM, Zahurak M, Shah K, Sidransky D, Westra WH,. Immunohistochemical detection of TP53 protein accumulation in head and neck cancer: correlation with TP53 gene alterations. Hum Pathol 1999; 30: 1221-1225.
25. Erber R, Conradt C, Homann N, et al. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 1998; 16: 1671-1679.
26. Temam S, Flahault A, Perie S, et al. TP53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2000; 18: 385-394.
27. Cabelguenne A, Blons H, de Waziers I, et al. TP53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol 2000; 18: 1465-1473.
28. Ganly I, Soutar DS, Brown R, Kaye SB,. TP53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy. Br J Cancer 2000; 82: 392-398.
29. Alsner J, Sorensen SB, Overgaard J,. TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. Radiother Oncol 2001; 59: 179-185.
30. Koch WM, Brennan JA, Zahurak M, et al. TP53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996; 88: 1580-1586.
31. Warnakulasuriya S, Soussi T, Maher R, Johnson N, Tavassoli M,. Expression of TP53 in oral squamous cell carcinoma is associated with the presence of IgG and IgA TP53 autoantibodies in sera and saliva of the patients. J Pathol 2000; 192: 52-57.
32. Boyle JO, Mao L, Brennan JA, et al. Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas. Am J Surg 1994; 168: 429-432.
33. Poeta ML, Manola J, Goldenberg D, et al. The Ligamp TP53 assay for detection of minimal residual disease in head and neck squamous cell carcinoma surgical margins. Clin Cancer Res 2009; 15: 7658-7665.
34. Ganly I, Kirn D, Eckhardt G, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000; 6: 798-806.
35. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001; 19: 289-298.
36. Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in TP53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 2000; 60: 6359-6366.
37. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885.
38. Nemunaitis J, Clayman G, Agarwala SS, et al. Biomarkers predict TP53 gene therapy efficacy in recurrent squamous cell carcinoma of the head and neck. Clin Cancer Res 2009; 15: 7719-7725.
39. Nemunaitis J, Nemunaitis J,. Head and neck cancer: response to TP53-based therapeutics. Head Neck 2011; 33: 131-134.
40. Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991; 66: 649-661.
41. Nicolas M, Wolfer A, Raj K, et al. NOTCH1 functions as a tumor suppressor in mouse skin. Nat Genet 2003; 33: 416-421.
42. Dotto GP,. Notch tumor suppressor function. Oncogene 2008; 27: 5115-5123.
43. Durinck S, Ho C, Wang NJ, et al. Temporal dissection of tumorigenesis in primary cancers. Cancer Discov 2011; 1: 137-143.
44. Bolos V, Grego-Bessa J, de la Pompa JL,. Notch signaling in development and cancer. Endocr Rev 2007; 28: 339-363.
45. Kageyama R, Ohtsuka T,. The Notch-Hes pathway in mammalian neural development. Cell Res 1999; 9: 179-188.
46. Wang NJ, Sanborn Z, Arnett KL, et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A 2011; 108: 17761-17766.
47. Baldus CD, Thibaut J, Goekbuget N, et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia. Haematologica 2009; 94: 1383-1390.
48. Fortini ME,. Gamma-secretase-mediated proteolysis in cell-surface- receptor signalling. Nat Rev Mol Cell Biol 2002; 3: 673-684.
49. Curry CL, Reed LL, Golde TE, Miele L, Nickoloff BJ, Foreman KE,. Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene 2005; 24: 6333-6344.
50. A notch signaling pathway inhibitor for patients with T-cell acute lymphoblastic leukemia/lymphoma (ALL). NCT01100152.
51. Study of MK-0752 in combination with tamoxifen or letrozole to treat early stage breast cancer. NCT00756717.
52. Extance A,. Alzheimer's failure raises questions about disease-modifying strategies. Nat Rev Drug Discov 2010; 9: 749-751.
53. Barbacid M,. ras genes. Annu Rev Biochem 1987; 56: 779-827.
54. Sathyan KM, Nalinakumari KR, Kannan S,. H-Ras mutation modulates the expression of major cell cycle regulatory proteins and disease prognosis in oral carcinoma. Mod Pathol 2007; 20: 1141-1148.
55. Saranath D, Chang SE, Bhoite LT, et al. High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India. Br J Cancer 1991; 63: 573-578.
56. Xu J, Gimenez-Conti IB, Cunningham JE, et al. Alterations of TP53, cyclin D1, Rb, and H-ras in human oral carcinomas related to tobacco use. Cancer 1998; 83: 204-212.
57. Paterson IC, Eveson JW, Prime SS,. Molecular changes in oral cancer may reflect aetiology and ethnic origin. Eur J Cancer B Oral Oncol 1996; 32B: 150-153.
58. Bos JL,. ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689.
59. Matthaios D, Zarogoulidis P, Balgouranidou I, Chatzaki E, Kakolyris S,. Molecular pathogenesis of pancreatic cancer and clinical perspectives. Oncology 2011; 81: 259-272.
60. Quinlan MP, Settleman J,. Isoform-specific ras functions in development and cancer. Future Oncol 2009; 5: 105-116.
61. Giehl K,. Oncogenic Ras in tumour progression and metastasis. Biol Chem 2005; 386: 193-205.
62. Castellano E, Downward J,. Role of RAS in the regulation of PI 3-kinase. Curr Top Microbiol Immunol 2010; 346: 143-169.
63. Murugan AK, Hong NT, Fukui Y, Munirajan AK, Tsuchida N,. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas. Int J Oncol 2008; 32: 101-111.
64. Cully M, You H, Levine AJ, Mak TW,. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006; 6: 184-192.
65. Qiu W, Schonleben F, Li X, et al. PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res 2006; 12: 1441-1446.
66. Singh B, Stoffel A, Gogineni S, et al. Amplification of the 3q26.3 locus is associated with progression to invasive cancer and is a negative prognostic factor in head and neck squamous cell carcinomas. Am J Pathol 2002; 161: 365-371.
67. Woenckhaus J, Steger K, Werner E, et al. Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma. J Pathol 2002; 198: 335-342.
68. Rogers SJ, Box C, Harrington KJ, Nutting C, Rhys-Evans P, Eccles SA,. The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck. Expert Opin Ther Targets 2005; 9: 769-790.
69. Ibrahim SO, Vasstrand EN, Liavaag PG, Johannessen AC, Lillehaug JR,. Expression of c-erbB proto-oncogene family members in squamous cell carcinoma of the head and neck. Anticancer Res 1997; 17: 4539-4546.
70. Rodrigo JP, Ramos S, Lazo PS, Alvarez I, Suarez C,. Amplification of ERBB oncogenes in squamous cell carcinomas of the head and neck. Eur J Cancer 1996; 32A: 2004-2010.
71. Mayo LD, Donner DB,. The PTEN, Mdm2, TP53 tumor suppressor-oncoprotein network. Trends Biochem Sci 2002; 27: 462-467.
72. Bjornsti MA, Houghton PJ,. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4: 335-348.
73. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M,. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004; 30: 193-204.
74. Hay N, Sonenberg N,. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-1945.
75. Segrelles C, Ruiz S, Perez P, et al. Functional roles of Akt signaling in mouse skin tumorigenesis. Oncogene 2002; 21: 53-64.
76. Sliva D,. Signaling pathways responsible for cancer cell invasion as targets for cancer therapy. Curr Cancer Drug Targets 2004; 4: 327-336.
77. Downward J,. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3: 11-22.
78. Massion PP, Taflan PM, Shyr Y, et al. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med 2004; 170: 1088-1094.
79. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
80. A study of the safety and activity of the MEK inhibitor given together with the AKT inhibitor to patients with multiple myeloma or solid tumor cancers. NCT01476137.
81. Rapamycin therapy in head and neck squamous cell carcinoma. NCT01195922.
82. MK2206 in treating patients with recurrent or metastatic head and neck cancer. NCT01349933.
83. Study of PX-866 and docetaxel in solid tumors. NCT01204099.
84. Phase 1 and 2 study of PX-866 and cetuximab. NCT01252628.
85. Schwarz S, Bier J, Driemel O, et al. Losses of 3p14 and 9p21 as shown by fluorescence in situ hybridization are early events in tumorigenesis of oral squamous cell carcinoma and already occur in simple keratosis. Cytometry A 2008; 73: 305-311.
86. Perez-Sayans M, Suarez-Penaranda JM, Gayoso-Diz P, Barros-Angueira F, Gandara-Rey JM, Garcia-Garcia A,. p16(INK4a)/CDKN2 expression and its relationship with oral squamous cell carcinoma is our current knowledge enough? Cancer Lett 2011; 306: 134-141.
87. Ohta S, Uemura H, Matsui Y, et al. Alterations of p16 and p14ARF genes and their 9p21 locus in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 107: 81-91.
88. Reed AL, Califano J, Cairns P, et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996; 56: 3630-3633.
89. Serrano M, Hannon GJ, Beach D,. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-707.
90. Morgan DO,. Principles of CDK regulation. Nature 1995; 374: 131-134.
91. Sherr CJ,. G1 phase progression: cycling on cue. Cell 1994; 79: 551-555.
92. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996; 56: 2488-2492.
93. Rosin MP, Cheng X, Poh C, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 2000; 6: 357-362.
94. van der Riet P, Nawroz H, Hruban RH, et al. Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 1994; 54: 1156-1158.
95. Reimers N, Kasper HU, Weissenborn SJ, et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 2007; 120: 1731-1738.
96. Brieger J, Pongsapich W, Mann SA, et al. Demethylation treatment restores hic1 expression and impairs aggressiveness of head and neck squamous cell carcinoma. Oral Oncol 2010; 46: 678-683.
97. Timmermann S, Hinds PW, Munger K,. Re-expression of endogenous p16ink4a in oral squamous cell carcinoma lines by 5-aza-2′-deoxycytidine treatment induces a senescence-like state. Oncogene 1998; 17: 3445-3453.
98. Wang L, Qi X, Sun Y, Liang L, Ju D,. Adenovirus-mediated combined P16 gene and GM-CSF gene therapy for the treatment of established tumor and induction of antitumor immunity. Cancer Gene Ther 2002; 9: 819-824.
99. A trial of LEE011 in patients with advanced solid tumors or lymphoma. NCT01237236.
100. Open label phase I study of P276-00 in patients with advanced refractory neoplasms. NCT00407498.
101. Phase I study of P276-00 in patients with advanced refractory neoplasms. NCT00407498.
102. A phase I study of LY2835219 in subjects with advanced cancer. NCT01394016.
103. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29: 4294-4301.
104. Westra WH, Taube JM, Poeta ML, Begum S, Sidransky D, Koch WM,. Inverse relationship between human papillomavirus-16 infection and disruptive TP53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res 2008; 14: 366-369.
105. Dickens P, Srivastava G, Loke SL, Larkin S,. Human papillomavirus 6, 11, and 16 in laryngeal papillomas. J Pathol 1991; 165: 243-246.
106. Stubenrauch F, Laimins LA,. Human papillomavirus life cycle: active and latent phases. Semin Cancer Biol 1999; 9: 379-386.
107. Gillison ML, D'Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100: 407-420.
108. D'souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML,. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis 2009; 199: 1263-1269.
109. Pai SI, Westra WH,. Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol 2009; 4: 49-70.
110. Park HW, Song SY, Lee TJ, Jeong D, Lee TY,. Abrogation of the p16-retinoblastoma-cyclin D1 pathway in head and neck squamous cell carcinomas. Oncol Rep 2007; 18: 267-272.
111. Begum S, Westra WH,. Basaloid squamous cell carcinoma of the head and neck is a mixed variant that can be further resolved by HPV status. Am J Surg Pathol 2008; 32: 1044-1050.
112. Klussmann JP, Weissenborn SJ, Wieland U, et al. Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 2001; 92: 2875-2884.
113. Ha PK, Pai SI, Westra WH, et al. Real-time quantitative PCR demonstrates low prevalence of human papillomavirus type 16 in premalignant and malignant lesions of the oral cavity. Clin Cancer Res 2002; 8: 1203-1209.
114. Li W, Thompson CH, O'Brien CJ, et al. Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. Int J Cancer 2003; 106: 553-558.
115. Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006; 24: 736-747.
116. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM,. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 2001; 92: 805-813.
117. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-269.
118. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
119. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95: 1459-1466.
120. Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010; 59: 626-629.
121. D'Souza G, Dempsey A,. The role of HPV in head and neck cancer and review of the HPV vaccine. Prev Med 2011; 53 (Suppl 1): S5-S11.
122. Centers for Disease Control and Prevention. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010; 59: 630-632.
123. Vogelstein B, Kinzler KW,. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-799.
124. Lee W, Jiang Z, Liu J, et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010; 465: 473-477.
125. Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B,. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A 2011; 108: 9530-9535.
126. Bonner JA, De Los Santos J, Waksal HW, Needle MN, Trummel HQ, Raisch KP,. Epidermal growth factor receptor as a therapeutic target in head and neck cancer. Semin Radiat Oncol 2002; 12 (3 Suppl 2): 11-20.
127. Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A, et al. Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer 2006; 42: 109-111.
128. Grandis JR, Tweardy DJ,. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53: 3579-3584.